Sotrovimab Or Xevudy Market Report 2026

Sotrovimab Or Xevudy Market Overview

• The Sotrovimab Or Xevudy market growth in the historic period has been driven by emergency authorization of covid-19 monoclonal antibodies, high hospitalization risk during early pandemic phases • Market expansion is supported by evolution of variant-resistant antibody therapies, growing focus on preparedness for future pandemics • Growth Driver: Impact Of Rising COVID-19 Cases On Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sotrovimab Or Xevudy Market?

Sotrovimab (Xevudy) is a monoclonal antibody treatment developed for the management of COVID-19. It is specifically designed to target the SARS-CoV-2 spike protein, preventing the virus from entering and infecting human cells. Sotrovimab is used for treating mild-to-moderate COVID-19 in patients at high risk of progressing to severe illness, offering an effective therapeutic option in early-stage infections. The main indication for sotrovimab or xevudy is COVID-19 early treatment and post-exposure prophylaxis. The COVID-19 early treatment refers to the use of sotrovimab (xevudy) to treat patients who are diagnosed with COVID-19 early in the course of the disease. This treatment is designed to reduce the severity of symptoms, prevent complications, and decrease the likelihood of hospitalization, particularly in individuals who are at high risk of severe disease. It is distributed through various channels such as hospitals pharmacies, retail pharmacies, and online pharmacies and is utilized by pediatric, adult, and geriatric.

What Is The Sotrovimab Or Xevudy Market Growth Forecast?

The growth in the forecast period can be attributed to evolution of variant-resistant antibody therapies, growing focus on preparedness for future pandemics, increased investment in antiviral biologics, expansion of outpatient infusion services, integration of monoclonal antibodies into standard care protocols. Major trends in the forecast period include increasing use of monoclonal antibody therapies, rising focus on early-stage viral treatment, expansion of targeted antiviral biologics, growing emphasis on high-risk patient protection, enhanced development of pandemic-response therapeutics.

Global Sotrovimab Or Xevudy Market Segmentation

1) By Indication: COVID-19 Early Treatment, Post-Exposure Prophylaxis 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Pediatric, Adult, Geriatric

What Are The Drivers Of The Sotrovimab Or Xevudy Market?

The rise in the prevalence of COVID-19 cases is expected to drive the growth of the sotrovimab or xevudy market going forward. COVID-19 is a disease caused by the SARS-CoV-2 virus, spreading through respiratory droplets and causing symptoms from mild fever to severe respiratory issues. Vaccines and hygiene practices help prevent its spread. COVID-19 cases are increasing due to factors such as new variants, reduced immunity, eased restrictions, seasonal indoor gatherings, and uneven vaccine coverage. Sotrovimab treats high-risk COVID-19 patients by neutralizing the virus early, preventing severe outcomes such as hospitalization or death. For instance, in March 2023, according to a report published by the Office for National Statistics, a UK-based government department for official statistics, as of March 2023, an estimated 1.9 million people in the UK (2.9% of the population) reported COVID. Most (92%) had COVID-19 over 12 weeks earlier, with 69% experiencing symptoms for over a year and 41% for over two years. Therefore, the rise in the prevalence of COVID cases is going to drive the growth of the sotrovimab or xevudy industry. The rise in healthcare investments is expected to drive the growth of the sotrovimab or xevudy market going forward. Healthcare investments refers to the total amount spent on healthcare services, including medical treatments, medications, and hospital care, within a specific period. Healthcare investments is rising due to factors such as an aging population, increasing healthcare needs, advancements in medical technology, and rising prices for services and medications. Investments in healthcare boost sotrovimab (xevudy) by supporting R&D, expanding production, and improving access for high-risk patients through partnerships and distribution networks. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department for official statistics, total healthcare expenditure saw a 5.6% increase in nominal terms from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth observed in 2022. Therefore, the rise in healthcare investments will drive the growth of the sotrovimab or xevudy industry.

Key Players In The Global Sotrovimab Or Xevudy Market

Major companies operating in the sotrovimab or xevudy market are GSK plc, Vir Biotechnology Inc.

What Are Latest Mergers And Acquisitions In The Sotrovimab Or Xevudy Market?

In February 2023, Vir Biotechnology, a U.S.-based biotechnology company, and GSK, a collaboration agreement to strengthen joint development efforts for Sotrovimab and VIR-7832. The updated agreement reaffirmed both companies’ commitment to advancing these monoclonal antibody programs and clarified shared responsibilities related to development, manufacturing, and commercialization. GlaxoSmithKline is a UK-based company developers and suppliers of sotrovimab

Regional Insights

North America was the largest region in the sotrovimab or xevudy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Sotrovimab Or Xevudy Market?

The sotrovimab or xevudy market consists of sales of pre-filled syringes and infusion kits. Values in this market are ‘factory gate’ values, representing the value of vaccines sold directly by manufacturers, either to governments, healthcare organizations, or distribution networks. This includes revenues from related services but excludes resales further along the supply chain or integration into other healthcare products.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sotrovimab Or Xevudy Market Report 2026?

The sotrovimab or xevudy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sotrovimab or xevudy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.